title: HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer.
abstract: OBJECTIVE
  We investigated potential associations between single-nucleotide polymorphisms (SNPs) in the heat shock protein beta-1 (HSPB1) gene and overall survival in US patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Using available genomic DNA samples from 224 patients with NSCLC treated with definitive radio(chemo)therapy, we genotyped 2 SNPs of HSPB1 (NCBI SNP nos. rs2868370 and rs2868371). We used both Kaplan-Meier cumulative probability and Cox proportional hazards analyses to evaluate the effect of HSPB1 genotypes on survival.
  
  
  RESULTS
  Our cohort consisted of 117 men and 107 women, mostly white (79.5%), with a median age of 70 years. The median radiation dose was 66 Gy (range, 63-87.5 Gy), and 183 patients (82%) received concurrent platinum-based chemotherapy. The most common genotype of the rs2868371 SNP was CC (61%). Univariate and multivariate analyses showed that this genotype was associated with poorer survival than CG and GG genotypes (univariate hazard ratio [HR] = 1.39, 95% confidence interval [CI], 1.02-1.90; P=.037; multivariate HR = 1.39; 95% CI, 1.01-1.92; P=.045).
  
  
  CONCLUSIONS
  Our results showed that the CC genotype of HSPB1 rs2868371 was associated with poorer overall survival in patients with NSCLC after radio(chemo)therapy, findings that contradict those of a previous study of Chinese patients. Validation of our findings with larger numbers of similar patients is needed, as are mechanical and clinical studies to determine the mechanism underlying these associations.
authors.affiliation: Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Xu
authors.forename: Qingyi
authors.initials: Q
authors.lastname: Wei
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Lopez Guerra
authors.forename: Li-E
authors.initials: LE
authors.lastname: Wang
authors.forename: Zhensheng
authors.initials: Z
authors.lastname: Liu
authors.forename: Daniel
authors.initials: D
authors.lastname: Gomez
authors.forename: Michael
authors.initials: M
authors.lastname: O'Reilly
authors.forename: Steven Hsesheng
authors.initials: SH
authors.lastname: Lin
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhuang
authors.forename: Lawrence B
authors.initials: LB
authors.lastname: Levy
authors.forename: Radhe
authors.initials: R
authors.lastname: Mohan
authors.forename: Honghao
authors.initials: H
authors.lastname: Zhou
authors.forename: Zhongxing
authors.initials: Z
authors.lastname: Liao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality* / Q000628:therapy; D059248:Chemoradiotherapy / Q000401:mortality; D005260:Female; D005838:Genotype; D055551:HSP27 Heat-Shock Proteins / Q000235:genetics*; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011336:Probability; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D015203:Reproducibility of Results; D012306:Risk; D016019:Survival Analysis; D014481:United States
chemical_list: D055551:HSP27 Heat-Shock Proteins; D009363:Neoplasm Proteins